epros Gives Update On Androxal With Respect To Recent FDA Advisory Panel Outcome And Announces Upcoming Presentation at Biocentury

By: via Benzinga
Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced that the conclusions of the FDA Advisory Panel that met on Wednesday, September ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.